Toxicity of glucocorticosteroids in autoimmune blistering diseases

Abstract

Glucocorticosteroids (GCs), have been the mainstay treatment for several dermatological diseases such as autoimmune bullous diseases (AIBDs). However, they come with a great cost of GCs-associated adverse events causing mortality and morbidity. Recently, a new measure to evaluate toxicity due to GCs' use has been demonstrated to be reliable. This review aimed to summarise toxicity attributed to GCs use and give more insight about this new toxicity index.

Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review

“… 2 , 3 However, long-term and high-dose treatment with systemic glucocorticoids (GCs) carries the risk of significant side effects, which contribute to morbidity and mortality in patients with AIBDs. 4 Therefore, a major goal of the management of AIBDs is to reduce the patient’s cumulative exposure to systemic steroids with the use of adjuvant steroid-sparing agents. 1 , 4 , 5 This review focuses on the treatment of bullous pemphigoid (BP) and pemphigus.…”

“… 4 Therefore, a major goal of the management of AIBDs is to reduce the patient’s cumulative exposure to systemic steroids with the use of adjuvant steroid-sparing agents. 1 , 4 , 5 This review focuses on the treatment of bullous pemphigoid (BP) and pemphigus. Given that pharmacologic side effects are crucial limitations while treating diseases, the objective is to assess the side effect profiles of steroid-sparing adjuvant therapies.…”